US · Healthcare · Biotechnology
EPS came in at -1.71 against a street estimate of -0.84 — a miss of 103.6%.
Analysts rate LB Pharmaceuticals Inc Common Stock a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $58.00.
| Fund | Stake |
|---|---|
| Deep Track Capital, LP | 10.39% |
| BlackRock Inc | 8.48% |
| RA Capital Management, LLC | 6.85% |
| Nantahala Capital Management, LLC | 6.53% |
| Trails Edge Capital Partners, LP | 4.72% |
| COMMODORE CAPITAL LP | 4.65% |
| JPMorgan Chase & Co | 4.64% |
| TCG Crossover Management, LLC | 4.49% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 LB PHARMACEUTICALS INC - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company appointed Susan G. Kozauer, M.D. as Chief Medical Officer, effective Se | 2026-09-15 |
| Board / officer change · Q3 2026 LB PHARMACEUTICALS INC - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • LB Pharmaceuticals Inc (ticker: LBRX, Nasdaq-listed) announced appointment of J | 2026-09-03 |
| Quarterly report · Q2 2026 LB PHARMACEUTICALS INC – 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $283.1 million in cash and cash equivalents as of June | 2026-08-11 |
| Results announced · Q3 2026 LB PHARMACEUTICALS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net loss Q2 2026: $51.6 million (vs. $4.9 million Q2 2025) • Net loss H1 202 | 2026-08-11 |
| Material agreement · Q3 2026 LB PHARMACEUTICALS INC - 8-K SUMMARY HEADLINE NUMBERS • Company raised approximately $150.0 million in gross proceeds from private placement (before | 2026-07-29 |
| Company announcement · Q3 2026 LB PHARMACEUTICALS INC - 8-K SUMMARY HEADLINE NUMBERS • Company: LB Pharmaceuticals Inc (Ticker: LBRX, Nasdaq) • Report Date: July 22, 2026 • Incorp | 2026-07-22 |
| Quarterly report · Q1 2026 LB PHARMACEUTICALS INC - Q1 2026 SUMMARY HEADLINE NUMBERS • Cash position: $320.7 million in cash and cash equivalents as of March 31, 2026 (up from | 2026-05-12 |
| Proxy statement · Q2 2026 LB PHARMACEUTICALS INC — 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class I directors—Robert A. Len | 2026-04-23 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for LB Pharmaceuticals Inc Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.